THE WNT SIGNALING CASCADE AS A POTENTIAL NOVEL BIOMARKER OF TRIPLE NEGATIVE BREAST CANCER (TNBC)

被引：0
|
作者：
Huelsewig, C. [1 ]
Ruckert, C. [1 ]
Goette, M. [1 ]
von Wahlde, M. K. [1 ]
Buchweitz, O. [2 ]
Kiesel, L. [1 ]
Pusztai, L. [3 ]
Liedtke, C. [1 ]
机构：
[1] Univ Munster, Munster, Germany
[2] Tagesklin Altonaer Str, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights
    Anwar, Mohammed Moustapha
    Shalaby, Manal
    Embaby, Amira M.
    Saeed, Hesham
    Agwa, Mona M.
    Hussein, Ahmed
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [42] Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights
    Mohammed Moustapha Anwar
    Manal Shalaby
    Amira M. Embaby
    Hesham Saeed
    Mona M. Agwa
    Ahmed Hussein
    Scientific Reports, 10
  • [43] The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC?
    Zhou, Y.
    Tian, Q.
    Wang, B-Y
    Yang, J.
    Zhao, S-D
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (07) : 2885 - 2897
  • [44] Biomarker comparison between androgen receptor - Positive-triple negative breast cancer (AR plus TNBC) and quadruple-negative breast cancer (QNBC)
    Xiu, J.
    Obeid, E.
    Gatalica, Z.
    Reddy, S.
    Goldstein, L. J.
    Link, J.
    Waisman, J.
    CANCER RESEARCH, 2016, 76
  • [45] PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
    Abraham, Jean E.
    Pinilla, Karen
    Grybowicz, Louise
    Dayimu, Alimu
    Demiris, Nikolaos
    Harvey, Caron
    Drewett, Lynsey M.
    Lucey, Rebecca
    Fulton, Alexander
    Roberts, Anne N.
    Worley, Joanna R.
    Chhabra, Anita
    Qian, Wendi
    Hardy, Richard M.
    Chan, Stephen
    Hickish, Tamas
    Tripathi, Devashish
    Venkitaraman, Ramachandran
    Persic, Mojca
    Aslam, Shahzeena
    Glassman, Daniel
    Raj, Sanjay
    Borley, Annabel
    Braybrooke, Jeremy P.
    Sutherland, Stephanie
    Staples, Emma
    Scott, Lucy C.
    Davies, Mark
    Palmer, Cheryl A.
    Moody, Margaret
    Churn, Mark J.
    Newby, Jacqueline C.
    Mukesh, B. Mukesh
    Chakrabarti, Amitabha
    Roylance, Rebecca R.
    Schouten, Philip C.
    Levitt, Nicola
    McAdam, Karen
    Armstrong, Anne C.
    Copson, Ellen R.
    McMurtry, Emma
    Tischkowitz, Marc
    Provenzano, Elena
    Earl, Helena
    CANCER RESEARCH, 2024, 84 (07)
  • [46] Subtyping of triple-negative breast cancer (TNBC): A cohort study
    Thomssen, Christoph
    Hartung, Caroline
    Porsch, Martin
    Stuckrath, Kathrin
    Buchmann, Jorg
    Kantelhardt, Eva J.
    Vetter, Martina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] HuR regulates aerobic glycolysis in triple negative breast cancer (TNBC)
    Dev, Arundhathi J. R.
    Gogia, Ajay
    Mathur, Sandeep R.
    Deo, S. V. S.
    Prasad, Chandra Prakash
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Receptor Concordance in Triple Negative Breast Cancer (TNBC) Recurrences.
    Killian, M. E.
    De Los Santos, J. F.
    Forero-Torres, A.
    Krontiras, H.
    CANCER RESEARCH, 2011, 71
  • [49] Triple negative breast cancer (TNBC): clinical utility of immunohistochemical classification
    Perez-Lopez, M.
    Arias, M.
    Penin, M.
    Garcia-Mata, J.
    Garcia-Caballero, T.
    BREAST, 2015, 24 : S40 - S40
  • [50] Does race affect outcomes in triple negative breast cancer (TNBC)?
    Ahmed, S.
    Mirza, M. M.
    Farooq, A.
    Kronish, L.
    Jahanzeb, M.
    Sachdev, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345